Repro Med Systems Inc (REPR) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2018

Exhibit 99.1

RMS Medical Products Announces Record Revenue and Profitability for 2018; Outlines Plan for Continued Strong Growth

CHESTER, NY / February 12, 2019 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (RMS Medical) today announced the latest financial results for the three and twelve months ending December 31, 2018 and outlined its plans for continued strong growth.

“2018 was a critical year for RMS,” said Don Pettigrew, President and Chief Executive Officer of RMS Medical.  “We refreshed our management team, strengthened our Board, entered into a new therapeutic indication and are preparing for future growth with the adoption of our Strategic Plan.  Our record results in the past year are evidence of the strength of this organization, and the value of the FREEDOM Syringe Infusion System, and we are looking to expand on this strength as we drive towards our vision of becoming the preferred drug delivery partner for specific infusion therapies in select markets.”  Don continued, “We have laid a solid foundation and developed a game plan to achieve our goals by the end of 2022 of $50 million net revenues, 70%+ Gross Margins and 20%+ annual organic revenue growth for each year.  While we may not always progress in a straight line, the team is focused on achieving these goals and I am confident we can get there.”

Don Pettigrew continued, “While 2018 was a record year financially, the organization underwent a lot of changes.  As a result, our numbers, especially in Q4 2018 include some charges related to our management reorganization that we do not expect to incur in the future.  We have broken out these charges in our financial results in an effort to show how the business would have performed on a normalized basis and they are described in the Operating Expenses, Non-GAAP Adjusted EBITDA and Non-GAAP Normalized Net Income sections below.”  Don concluded, “We look forward to the future of RMS Medical and executing on our plan to achieve its potential.”

Net Sales

For the twelve months ended December 31, 2018, net sales grew 12.4% to $17.4 million compared to $15.4 million for the twelve months ended December 31, 2017. Growth in net sales in 2018 was driven by increased penetration of the PIDD market for SubQ Ig, some early adoption of the CIDP market and clinical trials, which are a growing revenue source.

For the three months ended December 31, 2018, net sales totaled $4.3 million, up 3.5% from $4.1 million during the three months ended December 31, 2017.  While Q4 2018 net sales were above those achieved in our strongest quarter of 2017, fourth quarter sales were sequentially lower versus Q3 2018, mostly due to the timing of orders received in December but shipped in January 2019.